Managing Distress in Malignant Brain Cancer
Abstract
The current state of the science leaves neuro-oncology providers aware of their patients distress, yet without guidance for evidence-based treatment. Previous trials of evidence-based treatment for patients in this context did not include individuals with brain cancer. The purpose of this study is to assess the feasibility and acceptability of CALM, an evidenced-based treatment which aims to relieve distress following a brain cancer diagnosis, to meet military and civilian needs. Although research suggests CALM reduces distress in patients with advanced cancer, it has not been tested in brain cancer populations. Additionally, there may be a potential need for adaptations for this population, which will be studied in this trial. The first study is a single-arm, mixed-methods, Phase IIa, proof-of-concept trial (N=15) to inform CALM adaptations for Service Members, Veterans, their beneficiaries, and civilians with brain metastases. Upon completion of the Phase IIa/b trial, we will conduct a 2-year multi-arm randomized Phase IIc Pilot Trial (N = 60). CALM is being delivered individually to participants by trained CALM interventionists via telehealth. Recruitment goal for phase IIa/b was met on 5/4/23 with 15/15 participants recruited. Five patients withdrew before study completion. Ten patients have completed their course of CALM therapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2023
- Accession Number
- AD1215249
Entities
People
- Ashlee R Loughan
Organizations
- Virginia Commonwealth University